Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia

Addiction

Volumn 101, Issue 10, 2006, Pages 1499-1508

  Maher, Lisa ^a   Jalaludin, Bin ^b   Chant, Kerry G ^b   Jayasuriya, Rohan ^c   Sladden, Tim ^d   Kaldor, John M ^a   Sargent, Penny L ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d Northern Rivers Area Health Service   (Australia)

Author keywords

Hepatitis C; Injecting drug use; Prevention; Risk factors; Seroconversion

Indexed keywords

COCAINE; METHADONE;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; AWARENESS; BEHAVIOR; BLOOD ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INJECTION; MAJOR CLINICAL STUDY; MALE; NEEDLE; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RURAL AREA; SEROCONVERSION; SEROLOGY; URBAN AREA;

ADOLESCENT; ADULT; FEMALE; HEPATITIS C, CHRONIC; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; NEEDLE SHARING; NEW SOUTH WALES; RISK FACTORS; RISK-TAKING; RURAL HEALTH; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

EID: 33748376037     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01543.x     Document Type: Article

References (36)

1. Wasley A., Alter M. Epidemiology of hepatitis C. Geographical differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
2. MacDonald M., Crofts N., Kaldor J. Transmission of hepatitis C virus: rates, routes and cofactors. Epidemiol Rev 1996; 18: 137-48.
3. Thomas D. L., Astemborski J., Rai R. M., Anania F. A., Schaeffer M., Galai N. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
4. Alter M. J. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93-8.
5. Van Den Hoek J., Van Haastrecht H., Goudsmit J., De Wolf F., Coutino R. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990; 162: 823-6.
6. Judd A., Hickman M., Jones S., McDonald T., Parry J. V., Stimson G. V. et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London - prospective cohort study. BMJ 2005; 330: 24-5.
7. Villano S. A., Vlahov D., Nelson K. E., Lyles C. M., Cohn S. & Thomas D. L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 3274-7.
8. Garfein R. S., Doherty M. C., Monterroso E. R., Thomas D. L., Nelson K. E. & Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acq Immune Defic Synd Hum Retrovirol 1998; 18: S11-19.
9. Hagan H., Thiede H., Weiss N. S., Hopkins S. G., Duchin J. S. & Alexander E. R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.
10. Hahn J. A., Page-Shafer K., Lum P. J., Bourgois P., Stein E., Evans J. L. et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-64.
11. Hagan H., Thiede H., Des Jarlais D. C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004; 15: 543-9.
12. Crofts N., Aitken C. K. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-95. Med J Aust 1997; 167: 17-20.
13. Mansson A. S., Moestrup T., Nordenfelt E., Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000; 32: 253-8.
14. Brunton C., Kemp R., Raynel P., Harte D., Baker M. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. NZ Med J 2000; 113: 98-101.
15. Garten R. J., Lai S., Zhang J., Liu W., Chen J., Vlahov D. et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-8.
16. Thorpe L. E., Ouellet L. J., Hershow R., Bailey S. L., Williams I. T., Williamson J. et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-53.
17. Patrick D. M., Tyndall M. W., Cornelisse P. G., Li K., Sherlock C. H., Rekart M. L. et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J 2001; 165: 889-95.
18. Miller C. L., Johnston C., Spittal P. M., Li K., Laliberte N., Montaner J. S. et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-42.
19. Maher L. 2002 Don't leave us this way. Ethnography and injecting drug use in the age of AIDS. Int J Drug Policy 2006; 13: 311-25.
20. Maher L., Chant K., Jalaludin B., Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol 2004; 19: 1114-20.
21. NHMRC. A strategy for the management of hepatitis C in Australia. Canberra: Office of the National Health and Medical Research Council; 1997.
22. Pawlotsky J. M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-73.
23. Feachem R. Valuing the past . . . investing in the future: evaluation of the national HIV/AIDS strategy 1993-1994 to 1995-1996. Canberra: Australian Government Publishing Service; 1995.
24. Hunt N., Stillwell G., Taylor C., Griffiths P. Evaluation of a brief intervention to prevent initiation into injecting. Drugs Educ Prev Policy 1998; 5: 185-94.
25. Bourgois P., Prince B., Moss A. The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Hum Org 2004; 63: 253-64.
26. Maher L., Sargent P., Higgs P., Crofts N., Kelsall J. Risk behaviours of young Indo-Chinese injecting drug users in Sydney and Melbourne. Aust NZ J Public Health 2001; 25: 50-4.
27. Maher L. Sexed work: gender, race and resistance in a brooklyn drug market. Oxford: Oxford University Press; 1997.
28. Tyndall M. W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M. V. et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003; 17: 887-93.
29. Bourgois P. The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse 1998; 33: 2323-51.
30. Hunter G. M., Stimson G. V., Judd A., Jones S., Hickman M. Measuring injecting risk behaviour in the second decade of harm reduction: a survey of injecting drug users in England. Addiction 2000; 95: 1351-61.
31. De Irala J., Bigelow C., McCusker J., Hindin R., Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol 1996; 143: 725-32.
32. Latkin C. A., Vlahov D., Anthony J. C. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88: 517-26.
33. MacDonald M. A., Wodak A. D., Dolan K. A., Van Beek I., Cunningham P. H. & Kaldor J. M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-97. Med J Aust 2000; 172: 57-61.
34. Crofts N., Hopper J. L., Bowden D. S., Breschkin A. M., Milner R. & Locarnini S. A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159: 237-41.
35. Van Beek I., Buckley R., Stewart M., MacDonald M., Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70: 321-4.
36. Dore G. J., Law M., MacDonald M., Kaldor J. M. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171-84.